Home » Stocks » SBTX

Silverback Therapeutics, Inc. (SBTX)

Stock Price: $37.23 USD -0.41 (-1.09%)
Updated Apr 19, 2021 1:45 PM EDT - Market open
Market Cap 108.25M
Revenue (ttm) n/a
Net Income (ttm) -32.95M
Shares Out 2.91M
EPS (ttm) -11.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $37.23
Previous Close $37.64
Change ($) -0.41
Change (%) -1.09%
Day's Open 37.60
Day's Range 35.84 - 37.98
Day's Volume 54,164
52-Week Range 24.22 - 63.41

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

1 week ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

2 weeks ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

1 month ago - Business Wire

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

2 months ago - Business Wire

Silverback Therapeutics Inc (NASDAQ: SBTX) recently raised $277.7 million by selling 13.225 million shares in an initial public offering that were priced at $21 each. The Silverback Analyst: SVB Leerink...

3 months ago - Benzinga

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CAR, ARDX, CNNE, MPLN, SEER
4 months ago - Benzinga

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop syst...

4 months ago - Business Wire

The first week of the December IPO market saw eight IPOs and ten SPACs raise $3.9 billion, led by Chinese education technology group 17 Education & Technology Group. Two companies, Ondas and AMMO Inc., ...

Other stocks mentioned: FTCVU, KNTE, LOKBU, POWW, SEER, SGAMU, YQ
4 months ago - Seeking Alpha

The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.

Other stocks mentioned: SEER
4 months ago - Investors Business Daily

SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delive...

4 months ago - Business Wire

Silverback Therapeutics Inc. upsized its initial public offering to 10.00 million shares, and the expected pricing of the offering increased to between $19 and $20 a share. The Seattle-based biopharmace...

4 months ago - Market Watch

The signs were there: A couple of months ago, Silverback Therapeutics quickly pulled in $163 million in two back-to-back rounds for what CEO Laura Shawver called “an important growth phase.” As expected...

5 months ago - Endpoints News

Silverback Therapeutics is on a roll. After banking more than $160 million in venture capital this year, the immuno-oncology biotech filed on Tuesday to raise up to $100 million in its Wall Street debut...

5 months ago - Fierce Biotech

Silverback Therapeutics filed for an initial public offering on Tuesday, seeking additional capital as it develops targeted therapeutics for cancer, viral infections and other diseases, led by an execut...

5 months ago - GeekWire

Silverback Therapeutics, a Phase 1 biotech developing therapeutics for solid tumors and other diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

5 months ago - NASDAQ

Silverback Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

About SBTX

Silverback Therapeutics is a clinical-stage biopharmaceutical company with one product candidate in a Phase 1/1b clinical trial, and they are focused on leveraging their proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Their platform is used to strategically pair proprietary linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially,... [Read more...]

Industry
Biotechnology
IPO Date
Dec 4, 2020
CEO
Laura Shawver
Employees
54
Stock Exchange
NASDAQ
Ticker Symbol
SBTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SBTX stock is "Buy." The 12-month stock price forecast is 52.25, which is an increase of 40.34% from the latest price.

Price Target
$52.25
(40.34% upside)
Analyst Consensus: Buy